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Emblica officinalis Gaertn. belonging to family Euphorbiaceae is commonly known
as Indian gooseberry or “Amla” in India. It is used as a ‘rejuvenating herb’ in
traditional system of Indian medicine. It has been shown to possess antioxidant, anti-
inflammatory and anti-apoptotic effects. Thus, on the basis of its biological effects,
the present study was undertaken to evaluate the protective effect of the dried fruit
extract of the E. Officinalis (EO) in cisplatin-induced nephrotoxicity in rats and also
to evaluate the mechanism of its nephroprotection. The study was done on male
albino Wistar rats. They were divided into six groups (n = 6) viz. control, cisplatin-
control, cisplatin and EO (150, 300, and 600 mg/kg; p.o. respectively in different
groups) and EO only (600 mg/kg; p.o. only). EO was administered orally to the rats
for a period of 10 days and on the 7th day, a single injection of cisplatin (8 mg/kg;
i.p.) was administered to the cisplatin-control and EO treatment groups. The rats
were sacrificed on the 10th day. Cisplatin-control rats had deranged renal function
parameters and the kidney histology confirmed the presence of acute tubular necrosis.
Furthermore, there were increased oxidative stress, apoptosis and inflammation along
with higher expression of MAPK pathway proteins in the rat kidney from the cisplatin-
control group. Contrary to this, EO (600 mg/kg) significantly normalized renal function,
bolstered antioxidant status and ameliorated histological alterations. The inflammation
and apoptosis were markedly lower in comparison to cisplatin-control rats. Furthermore,
EO (600 mg/kg) inhibited MAPK phosphorylation which was instrumental in preserving
renal function and morphology. In conclusion, the results of our study demonstrated that
EO attenuated cisplatin-induced nephrotoxicity in rats through suppression of MAPK
induced inflammation and apoptosis.
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INTRODUCTION
Cisplatin (cis-diamminedichloroplatinum II or CDDP) is a
platinum compound which has a broad role in the management
of various solid malignancies such as head and neck, bladder,
lung, ovaries, testicles, and uterus (Oh et al., 2016). However,
during the course of chemotherapy, cisplatin may cause
ototoxicity, nephrotoxicity, myelosuppression, and peripheral
neuropathy (Oh et al., 2014). Among these undesirable effects,
nephrotoxicity is the most important dose limiting adverse effect
of cisplatin therapy, which primarily affects the S3 segment of
the proximal tubules (Bolisetty et al., 2016). It accounts for up
to 60% of acute kidney injury cases acquired from the hospital
and is associated with remarkably high morbidity and mortality
and approximately one fourth of patients initiated on high-dose
cisplatin have severe renal dysfunction while one third experience
kidney injury within few days of receiving cisplatin (Oh et al.,
2016). Clinically, cisplatin induced renal dysfunction manifests
as decline in renal plasma flow and glomerular filtration rate with
an increase in serum creatinine and blood urea nitrogen (Miller
et al., 2010). The proposed molecular mechanisms underlying
cisplatin nephrotoxicity involve oxidative stress, DNA damage,
apoptosis and exaggerated inflammatory response (Pabla and
Dong, 2008).
The oxidative stress has emerged as the main mechanism
in cisplatin-induced nephrotoxicity (dos Santos et al.,
2012; Oh et al., 2016). It has been reported that excess
reactive oxygen species (ROS) production as well as
antioxidant system depletions are consequent to cisplatin
administration (Domitrovic´ et al., 2013). The likely sources of
ROS during cisplatin administration include the mitochondrial
electron transport chain system (Pan et al., 2015), xanthine
oxidase (Yousef and Hussien, 2015), cytochrome P450 enzymes
(Pabla and Dong, 2008), and NADPH oxidase (Wang et al.,
2015). Since, ROS are highly reactive and unstable; they
may attack and modify cellular components such as lipids,
proteins, and DNA, resulting in cellular stress (Jaiman et al.,
2013). ROS accumulation also activates important signaling
pathways, including apoptotic pathway, which leads to cell
death in the event of cisplatin-induced nephrotoxicity (Song
et al., 2015). Cisplatin mediated oxidative stress provokes the
stimulation of a cascade of signaling proteins, including MAPKs
and NF-κB (Malik et al., 2015). This abnormal activation of
MAPK and NF-κB leads to release of inflammatory cytokines
subsequently aggravating the renal damage (Sahu et al.,
2014). The renal damage induced by cisplatin is managed
using hydration/diuretics, renal function monitoring and
adjustment of the cisplatin dose. However, renal toxicity still
occurs despite the use of these measures. Therefore, taking the
molecular pathways of cisplatin nephrotoxicity in consideration,
exploration of more effective nephroprotective therapeutic
options which would not affect the tumoricidal activity of
cisplatin is essential.
Several strategies have been evaluated to minimize
the nephrotoxicity caused by cisplatin. Recently, plant
derived natural compounds and their active constituents
are being evaluated for their beneficial effects in various
pathophysiological conditions (Athira et al., 2016). Emblica
officinalis (E. Officinalis) also known as Amla or Indian
Gooseberry is a natural fruit that serves as a rich source of
vitamin C (Krishnaveni and Mirunalini, 2010). It also contains
flavonoids, tannins, terpenoids and alkaloids which possess
various biological activities (Kim et al., 2005). The active
extracts of E. Officinalis have been demonstrated to exert
a wide range of activities such as antioxidant in alcohol-
induced oxidative damage in rat liver microsomes (Reddy
et al., 2014), anti-apoptotic in arsenic-induced apoptosis in
thymocytes of mice (Singh et al., 2013), anti-inflammatory in
rodent models of acute and chronic inflammation (Golechha
et al., 2014), anti-diabetic in type 2 diabetes in rats (Nain
et al., 2012), anti-hypertensive in DOCA salt induced
hypertension in rats (Bhatia et al., 2011) and anticancer in
cervical cancer cells (Mahata et al., 2013). Several studies
have also been conducted to investigate its beneficial effect
in kidney injury including cyclophosphamide induced renal
injury (Haque et al., 2001) and mycotoxin induced renal
toxicity (Verma and Chakraborty, 2008). Thus, the present
study was designed to investigate the beneficial effect of the
dried fruit extract of E. officinalis (EO) on cisplatin mediated
kidney injury by assessing its antioxidant, anti-apoptotic, and
anti-inflammatory properties on the kidney and further to
evaluate whether MAPK pathway is involved in mediating this
renoprotection.
MATERIALS AND METHODS
Plant Extract
The dried fruit extract of E. officinalis (EO) was obtained from
Sanat Products Limited, India (a WHO-GMP and ISO 9001
Accredited Herbal Extract Manufacturer Company). The batch
number of EO was 048001. The extract contained 31.58% w/w
of hydrolysable tannins emblicanin A and emblicanin B on dried
weight basis.
Chemicals
Cisplatin was obtained from Pfizer Products Pvt. Ltd., India.
Blood urea nitrogen (BUN) and serum creatinine kits were
procured from Transasia Bio-Medicals Ltd., India. Kits for
Terminal deoxynucleotide transferase dUTP nick end labeling
(TUNEL) assay (ApoBrduDNA fragmentation assay kit)
(Biovision Inc. California), tumor necrosis factor-α (TNF-α)
(Diaclone Tepnel Company, UK) and IL-6 (Ray Biotech,
Inc. Norcross, GA, USA) were used. Primary antibodies
against extracellular signal-regulated kinase 1/2 (ERK1/2),
phospho-ERK1/2 (p-ERK1/2), c-Jun N-terminal kinase (JNK),
phospho-JNK (p-JNK), Caspase-3, NF-κBp65, and β-actin
were procured from cell signaling technology, USA. Antibodies
for Bcl-2, Bax and p-38 were purchased from Abcam, UK.
Phospho-p38 (p-p38) antibody was obtained from Santa Cruz
biotechnology, USA. Secondary antibodies were from Merck
Genei Pvt. Ltd., India. All other chemicals used were of analytical
grade.
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Experimental Animals
Adult male albino Wistar rats aged 10–12 weeks old (weighing
150–200 g) were used for the study. All experimental procedures
were conducted after approval by Institutional Animal Ethics
Committee of All India Institute of Medical Sciences, New
Delhi (IAEC no. 604/IAEC/2011) and conformed to the Indian
National Science Academy Guidelines for care and use of animals
in research. During the study period, animals were kept in
polypropylene cages under conditions of ambient temperature
(25± 2◦C), relative humidity (60± 5%) and 12 h light/dark cycle
and provided food pellets (Ashirwad Industries Ltd, Chandigarh,
India) and tap water ad libitum.
A total of 36 male albino Wistar rats were randomly divided
into six groups containing six rats per group. The test drug, EO,
was dissolved in distilled water for administration to rats.
Group 1 (Control)
Rats received distilled water (2 ml/kg; p.o.) for the period of
10 days.
Group 2 (Cisplatin-Control)
Rats received distilled water (2 ml/kg; p.o.) for the period of
10 days and on the 7th day, a single injection of cisplatin
(8 mg/kg; i.p.) was administered to induce nephrotoxicity (Malik
et al., 2015).
Groups 3–5 (Treatment Groups)
Rats received EO (150–600 mg/kg; p.o.) daily for the period
of 10 days and on the 7th day, a single injection of cisplatin
(8 mg/kg; i.p.) was administered to induce nephrotoxicity.
Group 6 (EO Only)
Rats received EO (600 mg/kg; p.o.) for the period of 10 days.
On the 10th day, rats were anaesthetized with pentobarbitone
sodium (60 mg/kg; i.p.) and chest cavity was opened. Blood was
drawn via cardiac puncture, and centrifuged at 4000 rpm to
separate serum which was stored at −20◦C for measurement of
BUN, serum creatinine, TNF-α and IL-6 levels. After sacrificing,
one kidney from 6 rats per group was snap frozen in liquid
nitrogen and preserved in −80◦C and used for biochemical
estimation. The second kidney from 3 rats per group was
removed and preserved in 10% neutral buffered formalin for
histopatholgical and TUNEL assay and kidney from the other 3
rats per group were snap frozen in liquid nitrogen and stored in
−80◦C for western blot analysis.
Assessment of Kidney Function
Parameters
Serum creatinine and BUN levels were measured using respective
commercially available kits.
Measurement of Renal
Oxidant–Antioxidant Parameters
Kidney sample was removed from −80◦C, thawed, weighed and
10% homogenate was prepared in ice-chilled phosphate buffer
(0.1 M, pH 7.4). The tissue homogenate was divided into two
parts. One part of this homogenate was used for the estimation
of malondialdehyde (MDA) level and reduced glutathione (GSH)
content. The other part of this tissue homogenate was centrifuged
at 5000 rpm and supernatant thus obtained was used for
the estimation of superoxide dismutase (SOD), catalase (CAT)
enzyme activities and protein content.
Estimation of MDA Level
MDA level was estimated by the method described by Ohkawa
et al. (1979). To the 0.1 ml tissue homogenate, 0.5 ml of 8.1%
sodium dodecyl sulfate, 1.5 ml of 20% acetic acid and 1.5 ml of
0.8% thiobarbituric acid was added, vortexed and heated at 95◦C
for 60 min. After cooling, 5 ml of butanol:pyridine (15:1) mixture
was added to extract pink color complex. The pink organic layer
was separated and absorbance read at 532 nm. The amount of
MDA was calculated by extrapolation from the MDA standard
curve and expressed as nmole/g tissue.
Estimation of GSH Content
GSH was measured by the method described by Moron et al.
(1979). Firstly, homogenate was centrifuged with an equal
volume of 10% trichloroacetic acid. To the 0.1 ml of supernatant,
3 ml Na2HPO4 (0.3 M; pH 8.0) and 0.5 ml of 5,5′-dithiobis (2-
nitrobenzoic acid) prepared in 1% trisodium citrate were added
and mixed thoroughly. The absorbance of yellow color formed
was read at 412 nm. The amount of GSH was determined by
extrapolation from standard curve and expressed as µmole/g
tissue.
Estimation of SOD
Superoxide dismutase enzyme activity was determined by the
method described by Marklund and Marklund (1974). To the
0.1 ml supernatant, 2.95 ml of phosphate buffer (0.1 M; pH
8.4) and 0.05 ml of pyrogallol (7.5 mM) was added and the
change in absorbance was recorded at an interval of 60 s for
2 min at 420 nm. One unit of enzyme activity was defined as
the amount of enzyme required to produce 50% inhibition of
pyrogallol autoxidation under assay conditions and expressed as
U/mg protein.
Estimation of CAT
CAT enzyme activity was estimated by the method described by
Aebi (1984). To the 0.05 ml of supernatant, 1 ml of phosphate
buffer (50 mM; pH 7.0) and 1.0 ml of hydrogen peroxide (H2O2)
was added. Immediately, thereafter, change in the absorbance was
recorded for 30 s at an interval of 5 s at 240 nm. One unit of CAT
enzyme activity is equal to 1 µmol of H2O2 decomposed per min
and expressed as U/mg protein.
Estimation of Protein Content
Protein was measured by a method described by Bradford (1976).
To the supernatant, Bradford reagent was added and vortexed.
Blue color formed was measured at 595 nm. The amount of
protein was determined by standard curve and expressed as
mg/ml.
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Measurement of Serum
Pro-inflammatory Cytokines Level
TNF-α and IL-6 levels were assessed in serum using commercially
available ELISA kits as per manufacturer instructions.
Histopathological Examination
For histopathological evaluation, paraffin blocks were made from
kidney tissue preserved in formalin. The tissue sections of 5-µm
thickness were cut using microtome (Leica RM 2125, Germany).
These sections were stained with hematoxylin and eosin (H&E)
and studied under light microscope (Dewinter Technologies,
Italy).
TUNEL Assay
TUNEL assay was performed for detection of apoptosis in the
renal tissue. TUNEL assay was performed according to the
method described by Malik et al. (2015). Briefly, sections were
incubated with Proteinase K for 30 min to enhance tissue
permeability and then treated with 30% H2O2 in methanol for
15 min to diminish any endogenous peroxidase activity. Later,
sections were incubated with complete labeling reaction buffer
and antibody solution, each for 1 h and 30 min. Following this,
3,3′-diaminobenzidine (DAB) solution was added and at least five
fields in each slide were checked for any TUNEL positive cells in
each group.
The pathologist evaluating histopathological and TUNEL
slides was blinded to the treatment groups.
Western Blot Analysis
For western blot analysis, kidneys were removed from −80◦C,
thawed and weighed. Then tissues were homogenized in
Radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl,
10% Triton X-100, 0.5% Sodium deoxycholate, 0.1% Sodium
dodecyl sulfate, 50 mM Tris base), along with protease inhibitor
(Sigma Aldrich, USA). The homogenate was centrifuged at
12000 rpm for 20 min at 4◦C and supernatant was used for
measurement of protein concentration by using the method
described by Bradford (1976). Protein equivalent to 40 µg
was separated by the sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). Separated proteins were then
transferred to a nitrocellulose membrane and then blocked with
3% bovine serum albumin (BSA) for 1 h. After that, membrane
was blocked with primary antibodies for ERK1/2, p-ERK1/2,
JNK, p-JNK, p38, p-p38, Bcl-2, Bax, Caspase-3, NF-κBp65 and
β-actin (1:3000) overnight at 4◦C. The primary antibodies were
detected with HRP-conjugated secondary antibodies (1:5000) for
2 h at room temperature. The antigen-antibody reaction was then
visualized with enhanced chemiluminscence (ECL) kit according
to manufacturer’s instructions. The band intensity was measured
using image-j software.
Statistical Analysis
Data of all experimental groups were analyzed by one way
analysis of variance (ANOVA) followed by post hoc Tukey-
Kramer multiple comparison test using the Graph Pad InStat
software. Data are expressed as mean ± SEM and values for
P < 0.05 were considered as statistically significant.
RESULTS
Effect of EO on Kidney Function
Parameters
The kidney function parameters such as serum creatinine and
BUN levels were measured in all treatment groups to assess
renal function. Cisplatin injection resulted in significant increase
in serum creatinine (P < 0.001) and BUN levels (P < 0.001)
in comparison to control group. This elevation in serum
creatinine and BUN levels suggests significant kidney damage
and confirmed the induction of nephrotoxicity in cisplatin
control group. EO (600 mg/kg) pretreatment significantly
(P < 0.01) normalized serum creatinine and BUN levels as
compared to cisplatin-control group. However, no significant
effect was observed at two lower doses (150 and 300 mg/kg)
(Table 1).
Effect of EO on Renal
Oxidant–Antioxidant Parameters
In cisplatin-control rats, there was a significant (P < 0.001)
increase in the level of MDA, a marker of lipid peroxidation,
along with reduction in the level of antioxidants GSH (P< 0.001),
SOD (P < 0.01), and CAT (P < 0.01) in comparison to control
group. Interestingly, EO (600 mg/kg) pretreatment significantly
restored the kidney antioxidant status. This is depicted by
increase in the activities of GSH (P < 0.01), SOD (P < 0.05) and
CAT (P < 0.05) and decrease in the level of MDA (P < 0.05) as
TABLE 1 | Effect of EO on renal function tests (serum creatinine and BUN) and biochemical parameters.
Groups Sr. Creatinine (mg/dl) BUN (mg/dl) MDA (nmol/g tissue) GSH (µmol/g tissue) SOD (U/mg protein) CAT (U/mg protein)
Control 0.57 ± 0.028 28.59 ± 1.62 60.50 ± 3.44 0.29 ± 0.012 3.98 ± 0.41 4.73 ± 0.42
Cis-C 1.45 ± 0.052∗∗∗ 53.95 ± 2.67∗∗∗ 109.81 ± 3.75∗∗∗ 0.16 ± 0.014∗∗∗ 2.42 ± 0.33∗∗ 2.36 ± 0.65∗∗
EO 150+Cis 1.37 ± 0.075††† 50.35 ± 1.72††† 102.94 ± 4.54††† 0.18 ± 0.015††† 2.91 ± 0.18 3.61 ± 0.53
EO 300+Cis 1.29 ± 0.048††† 46.01 ± 2.05††† 96.63 ± 4.63††† 0.21 ± 0.012†† 3.02 ± 0.19 4.13 ± 0.30
EO 600+Cis 1.18 ± 0.057†††## 42.46 ± 1.66†††## 91.66 ± 3.38†# 0.24 ± 0.014## 3.57 ± 0.15# 4.42 ± 0.26#
EO 600 only 0.62 ± 0.031 31.65 ± 1.35 71.01 ± 3.71 0.32 ± 0.012 3.96 ± 0.18 4.92 ± 0.33
BUN, blood urea nitrogen; MDA, malondialdehyde; GSH, reduced glutathione; SOD, superoxide dismutase; CAT, catalase. Data are expressed as mean ± SEM of 6 rats
per group. ∗∗P < 0.01, ∗∗∗P < 0.001 versus control group; †P < 0.05, ††P < 0.01, †††P < 0.001 versus control group; #P < 0.05, ##P < 0.01 versus Cis-C group.
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compared to the cisplatin-control rats. Moreover, the two lower
doses (150 and 300 mg/kg) of EO failed to exert any beneficial
effect on the kidney antioxidant status (Table 1).
Effect of EO on Serum Inflammatory
Cytokines Level
Cisplatin administration is known to release pro-inflammatory
cytokines in serum. Thus, there was a significant (P < 0.001)
increase in serum pro-inflammatory cytokines level (TNF-α and
IL-6) in the cisplatin-control group as compared to the rats in
the control group. EO (600 mg/kg) pretreatment significantly
(P < 0.01) prevented the increase in the serum cytokines level as
compared to the cisplatin-control group. However, no significant
difference in the levels of these cytokines was observed with the
lower doses of EO (150 and 300 mg/kg) (Table 2).
Effect of EO on Renal Histopathology
The histopathological evaluation of control and EO only groups
demonstrated normal architecture of tubules with no evidence
of inflammation (Figures 1A,F). The kidney sections from the
cisplatin-control rats showed tubular atrophy, denudation of
epithelium and infiltration of inflammatory cells (Figure 1B). In
the groups, pretreated with 150 and 300 mg/kg dose of EO, there
was marked and moderate tubular damage and inflammation
respectively (Figures 1C,D). However, the highest dose of EO i.e.,
600 mg/kg exerted significant nephroprotection and a marked
absence of tubular necrosis and inflammation in the kidneys was
observed (Figure 1E).
Thus, on the basis of results of the above mentioned
parameters, EO at the dose of 600 mg/kg was found to exert
maximum nephroprotection. Hence, this dose was used for
further TUNEL and western blot analysis.
Effect of EO on Apoptosis and
Inflammation
The apoptosis in the renal tissue was assessed by detecting the
expression of apoptotic proteins in all groups. In cisplatin-control
group, there was significantly increased expression of pro-
apoptotic proteins [Bax (P < 0.001) and Caspase-3 (P < 0.001)]
and decreased expression of Bcl-2 (P < 0.001), an anti-apoptotic
protein. Furthermore, there was increased DNA fragmentation
TABLE 2 | Effect of EO on serum pro-inflammatory cytokines level.
Groups TNF-α (pg/ml) IL-6 (pg/ml)
Control 37.35 ± 1.49 9.5 ± 0.46
Cis-C 58.17 ± 2.38∗∗∗ 17.92 ± 0.91∗∗∗
EO 150+Cis 54.95 ± 2.92††† 16 ± 0.90†††
EO 300+Cis 50.07 ± 1.87†† 14.21 ± 0.94††
EO 600+Cis 46.46 ± 1.84†## 12.62 ± 0.65†##
EO 600 only 38.51 ± 1.64 10.29 ± 0.65
TNF-α, tumor necrosis factor-α; IL-6, interleukin-6. Data are expressed as
mean ± SEM of 6 rats per group. ∗∗∗P < 0.001 versus control group; †P < 0.05,
††P < 0.01, †††P < 0.001 versus control group; ##P < 0.01 versus Cis-C group.
and increased number of TUNEL positive cells in the cisplatin-
control group as compared to the control group. However, EO
(600 mg/kg) treatment group reduced the apoptosis as there
was significantly (P < 0.05) increased expression of Bcl-2 and
decreased expression of Bax, Caspase-3 along with decreased
DNA fragmentation as compared to cisplatin-control group. This
confirms the anti-apoptotic effect of EO in renal tissue (Figures 2
and 3).
Further, western blot analysis was performed to determine
the expression of NF-κBp65 in the renal tissue. Cisplatin-control
rats demonstrated significantly (P < 0.01) increased level of NF-
κBp65 whereas treatment with EO (600 mg/kg) attenuated this
effect (P < 0.05) (Figure 3).
Effect of EO on MAPK Signaling Pathway
In cisplatin-control group, there was increased phosphorylation
of ERK1/2, JNK and p38 proteins as compared to control
rats. The increased phosphorylation of these proteins mediated
apoptosis and inflammation in the cisplatin-control group.
Contrary to this, EO (600 mg/kg) treatment halted the activation
of this pathway and prevented apoptosis and inflammation in the
renal tissue (Figure 4).
DISCUSSION
The current study has demonstrated the renoprotective effect
of EO in cisplatin-induced acute renal toxicity in rats.
The administration of EO virtually ameliorated most of the
deleterious effects of cisplatin. This renoprotection was evident
from improved functional as well as structural renal profiles,
blunting of oxidative stress, inflammation, and apoptosis. Our
results further provided evidence that this improvement was
mediated by suppression of the MAPK signaling cascade.
Cisplatin’s chemotherapeutic applicability is limited by renal
toxicity and the latter occurs due to accumulation of cisplatin into
the renal tubular cells which subsequently leads to renal tubular
cell injury and renal cell death which appears histologically as
tubular atrophy (Pabla et al., 2009). Many studies have proposed
that cisplatin is also injurious to renal vasculature which results
in decreased blood flow leading to ischemic injury of the kidneys,
appearing as a decline in the glomerular filtration rate which
is reflected as increased serum creatinine and BUN levels (Xu
et al., 2015). In our study, we observed increased levels of
serum creatinine and BUN suggesting renal damage due to
cisplatin. Serum creatinine is the waste metabolic product and
is formed due to breakdown of creatine phosphate in muscle.
Normally, it is excreted by the kidneys, primarily by glomerular
filtration but also by proximal tubular secretion with little or no
reabsorption. If there is deterioration in kidney function, serum
level of creatinine rises (El-Naga, 2014; Changizi-Ashtiyani et al.,
2016; El-Naga and Mahran, 2016). Also, concomitant decline in
urinary creatinine clearance is observed vis a vis raised serum
creatinine levels. Infact, decrease in urinary creatinine clearance
due to cisplatin-induced kidney injury has been reported by other
researchers (Quesada et al., 2012; Nojiri et al., 2015). Although,
we have not measured the urinary creatinine clearance in this
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FIGURE 1 | Light microscopic study (H&E) of renal tissue in various experimental groups. (A) Control; (B) Cis-C; (C–E) EO 150, 300, 600 mg/kg+Cis
respectively; (F) EO 600 mg/kg only. (→): acute tubular necrosis; (n = 3; 20X; scale bar 100 µm).
FIGURE 2 | Effect of EO on TUNEL positivity (A–C; 20X; scale bar 100 µm) in various experimental groups. (A) Control; (B) Cis-C; (C) EO 600 mg/kg+Cis.
(→): tubular cell apoptosis.
particular study, the changes in serum creatinine and BUN
levels observed here were clearly accompanied by changes in
renal histology, further suggesting renal function deterioration
in cisplatin-treated animals. There was marked renal tubular
atrophy and denudation of epithelium following intraperitoneal
administration of 8 mg/kg cisplatin. Administration of EO
600 mg/kg, significantly normalized serum creatinine and BUN
levels and also preserved the histology of renal tubular cells.
Numerous studies have depicted the key role of oxidative
stress in the pathophysiology of cisplatin-induced renal cell
death (Song et al., 2015). Once cisplatin reaches the tubular
cells, it rapidly reacts with thiol-containing molecules including
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FIGURE 3 | Effect of EO on (A): NF-κBp65; (B) Bcl-2; (C) Bax; (D) Caspase-3 levels in various experimental groups. Data are expressed as mean ± SEM of
3 rats per group. ∗∗P < 0.01, ∗∗∗P < 0.001 versus control group; †P < 0.05, ††P < 0.01, †††P < 0.001 versus control group; #P < 0.05 versus Cis-C group.
glutathione by being converted to a highly reactive electrophile.
This positively charged electrophile is generated by replacement
of the chloride ligands of cisplatin with water molecules.
Cisplatin also increases ROS synthesis by inducing mitochondrial
dysfunction and disrupting the electron transport chain. Due to
their unstable configuration, ROS reacts with membrane lipids,
cellular proteins and DNA resulting in their modification leading
to cellular stress (Pabla and Dong, 2008). Lipid peroxidation
is a consequence of excessive ROS production. It leads to
increased level of MDA (a lipid peroxidation marker). The
rise in MDA levels following cisplatin administration in vivo
has been observed in our study and has also been reported
by other workers (Yüce et al., 2007). Excessive ROS is tackled
by endogenous antioxidants. However, when the synthesis of
ROS overrides its destruction, there is overconsumption of these
antioxidants. This consumption has also been demonstrated
previously in cisplatin nephrotoxicity models (Al-Majed et al.,
2006). Similarly, there was consumption of glutathione and other
endogenous antioxidants such as SOD and CAT in the cisplatin-
control group of our study. However, pretreatment with EO
maintained glutathione and other antioxidants at near normal
levels in the renal tissue. This supports the antioxidant activity
of EO which has been documented in the past (Golechha et al.,
2012; Dutta and Sahu, 2013; Singh et al., 2014). Previous studies
have shown that active constituents such as emblicanins A and B,
gallic acid, and ellagic acids present in E. officinalis are responsible
for its antioxidant activity (Feeney, 2004). Furthermore, free
radical scavenging property of E. officinalis has been reported
to be near to that of L-ascorbic acid, a well known antioxidant
(Muthuraman et al., 2011).
Though oxidative stress is a known promoter of apoptosis,
cisplatin itself directly induces apoptotic cell death which has
been shown by in vitro and in vivo studies (Tsuruya et al.,
2003; Seth et al., 2005; Zhou et al., 2013). According to
past reports, renal tubular epithelial cell apoptosis induced
by cisplatin is primarily via the mitochondrial pathway (Liu
et al., 2014). Cisplatin induced apoptosis has been shown
to be regulated by the pro-apoptotic protein Bax and the
anti-apoptotic protein Bcl-2 (Jiang et al., 2009). It has been
shown that cisplatin induces activation of Bax genes (Wei
et al., 2007). Bax protein eventually undergoes a conformational
change and binds to mitochondrial membrane and subsequently
causes the release of cytochrome c from mitochondria leading
to apoptosis (Tayem et al., 2006). In contrast, the anti-
apoptotic protein Bcl-2 stabilizes the mitochondrial membrane
potential thereby inhibiting cytochrome c release and inhibiting
apoptosis (Cummings and Schnellmann, 2002). Therefore, Bax
and Bcl-2 are crucial in regulating apoptosis. In our experiment,
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FIGURE 4 | Effect of EO on (A) ERK1/2 and p-ERK1/2; (B) JNK and p-JNK; (C) p38 and p-p38 in various experimental groups. Data are expressed as
mean ± SEM of 3 rats per group. ∗∗P < 0.01, ∗∗∗P < 0.001 versus control group; #P < 0.05, ##P < 0.01 versus Cis-C group.
significantly higher Bax and Caspase-3 and lower Bcl-2 levels
were observed in cisplatin-control group. This shows that
cisplatin increases Bax and Caspase-3 while lowering Bcl-
2 expression of renal tissues whereas pretreatment with EO
(600 mg/kg) decreased the Bax and Caspase-3 and increased
Bcl-2 levels. TUNEL assay was performed to assess the DNA
fragmentation. The TUNEL positivity was observed to be high in
cisplatin treated rats and significantly reduced in EO pretreated
group. These findings support the previously documented anti-
apoptotic activity of E. Officinalis (Singh et al., 2013, 2014). Thus,
it can be proposed that the renoprotection of EO is mediated by
its antioxidant and anti-apoptotic properties.
Strong evidence suggests that the pathogenesis of cisplatin
induced renal cell apoptosis is associated with the release
of inflammatory cytokines and mediators, including IL-1, IL-
6, and TNF-α (Zhang et al., 2007; Guerrero-Beltrán et al.,
2012; Zirak et al., 2014). Additionally, NF-κB which is a
transcription factor regulating the modulation of inflammatory
and immunomodulatory genes, is associated with the process
of cisplatin induced renal inflammation (Benedetti et al., 2013).
NF-κB activity is inhibited by the specific IκB in the cytoplasm,
the latter being rapidly cleared by IKKβ upon activation of NF-
κB. NF-κB is released and then translocates to the nucleus, where
it activates the transcription of target genes (Ma et al., 2015).
Our study has shown that cisplatin-control group has a higher
expression of activated NF-κB, IL-6 and TNF-α in comparison
to the control rats. Interestingly, EO significantly attenuated the
levels of inflammatory cytokines and also blunted the expression
of NF-κB. The polyphenol rich components of ethanolic extract
of E. officinalis have previously been demonstrated to reduce
expression of NF-κB in a similar fashion (Kim et al., 2010).
Therefore, the attenuation of cisplatin induced nephrotoxicity
with EO in our study may also be mediated by the anti-
inflammatory property of EO.
Based on the ability of EO to suppress the phosphorylation
of members of the NF-κB cascade pathway and inflammation,
we further investigated the effect of EO on the upstream
signaling components of NF-κB, the MAPK family. MAPK family
comprises of three major serine/threonine kinase proteins such
as ERK 1/2, JNK and p38 which are associated with cell growth
and differentiation, and are extensively linked to inflammation,
apoptosis and cell death. Several in vitro and in vivo studies have
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demonstrated the role of p38 and JNK in cisplatin-induced
nephrotoxicity (Ramesh and Reeves, 2005, 2006; Francescato
et al., 2007). ERK1/2 promotes apoptosis by decreasing the
production of cytochrome c, phosphorylation of caspase-3,
and accelerating the translocation of Bax from cytosol to
mitochondria during cisplatin-induced renal cell death (Kim
et al., 2014). Cisplatin-induced phosphorylation of JNK induces
inflammation of the kidney tubules, apoptosis, and kidney
dysfunction (Ma et al., 2015). As anticipated, in our study,
cisplatin injection increased the phosphorylation of p38, ERK1/2
and JNK. Pre-treatment with EO, however, ameliorated this
increase. Our results are also in line with our study which
has demonstrated ERK1/2 modulated effect of E. officinalis
(Sumitra et al., 2009). Hence, we can convincingly propose that
EO mediates its nephroprotective action by regulating MAPK
signaling pathway.
In summary, our findings demonstrate that EO treatment
alleviates the cisplatin-induced cytotoxicity in kidney through
suppressing the ROS mediated activation of MAPKs and NF-
κB signaling cascades. Furthermore, EO treatment inhibits the
synthesis of intracellular inflammatory cytokines and mediators.
Our study suggests that EO has good potential and may be further
evaluated clinically for treating cisplatin-induced nephrotoxicity.
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